Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.61 |
| ▸ | CES1 | P23141 | 3/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | ACKR3 | P25106 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29669985 | 1.00 | CES2 (0.61) | CES2CES1PTPN1ACKR3L3MBTL1 | |
| SCHEMBL2099037 | 0.84 | CES2 (0.61) | CES2CES1PTPN1 | |
| SCHEMBL932166 | 0.82 | PTPN1 (0.48) | CES2CES1PTPN1RAB9A | |
| SCHEMBL691531 | 0.82 | DGAT1 (0.61) | CES2CES1PTPN1RAB9A | |
| SCHEMBL30195364 | 0.82 | PTPN1 (0.52) | CES2CES1PTPN1RAB9A | |
| SCHEMBL29993519 | 0.82 | DGAT1 (0.61) | CES2CES1PTPN1RAB9A | |
| SCHEMBL615669 | 0.82 | PTPN1 (0.52) | CES2CES1PTPN1RAB9A | |
| SCHEMBL1701610 | 0.82 | PTPN1 (0.52) | CES2CES1PTPN1RAB9AKCNH2 | |
| SCHEMBL3907360 | 0.82 | CES2 (0.53) | CES2CES1ACKR3L3MBTL1RAB9A | |
| SCHEMBL8584 | 0.82 | CES2 (0.63) | CES2CES1ACKR3L3MBTL1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 349 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288315-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUND | DAISO CO., LTD. (JP) | 2011-11-24 | — | — | US | claimed |
| EP-2325178-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUND | DAISO CO., LTD. (JP) | 2011-05-25 | — | — | EP | claimed |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2025-12-25 | — | — | US | disclosed |
| US-20250257058-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMO | US GOV VETERANS AFFAIRS (US) | 2025-08-14 | — | — | US | disclosed |
| US-20250170117-A1 | MODULATORS OF ACKR3 AND USES THEREOF | INTERAX BIOTECH AG (CH) | 2025-05-29 | — | — | US | disclosed |
| EP-4556476-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | Ildong Pharmaceutical Co., Ltd. (KR) | 2025-05-21 | — | — | EP | disclosed |
| EP-4508038-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMO | The United States Government as represented by the Department of Veterans Affairs (US) | 2025-02-19 | — | — | EP | disclosed |
| EP-4486739-A1 | MODULATORS OF ACKR3 AND USES THEREOF | InterAx Biotech AG (CH) | 2025-01-08 | — | — | EP | disclosed |
| WO-2024028808-A1 | AROMATIC COMPOUNDS FOR USE AS PROTEIN PHOSPHATASE 2A (PP2A) MODULATORS | RAPPTA THERAPEUTICS OY (FI) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024014885-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | 일동제약(주) | 2024-01-18 | — | — | WO | disclosed |
| EP-3212636-B1 | NEW PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2023-11-29 | — | — | EP | disclosed |
| US-5439917-A | Phenyl-pyrrolo(2,3-b)pyridine antisecretory agent of gastric acid; adenosine triphosphatase enzyme inhibitor | AKTIEBOLAGET ASTRA (SE) | 1995-08-08 | — | — | US | disclosed |
| EP-0617031-A1 | Orally active azole derivates | J. URIACH & CIA. S.A. (ES) | 1994-09-28 | — | — | EP | disclosed |
| EP-0580616-A1 | NEW ACTIVE COMPOUNDS | Astra Aktiebolag (SE) | 1994-02-02 | — | — | EP | disclosed |
| EP-0509974-A1 | Pyrrolo[2,3-b]pyridines having therapeutic activity and a process for the preparation thereof | Astra Aktiebolag (SE) | 1992-10-21 | — | — | EP | disclosed |
| WO-1992017477-A1 | NEW ACTIVE COMPOUNDS | AKTIEBOLAGET ASTRA (SE) | 1992-10-15 | — | — | WO | disclosed |
| EP-0174769-B1 | ANTIFUNGAL AZOLE COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-11-21 | — | — | EP | disclosed |
| US-4925863-A | 1,3-DI(1,2,4-TRIAZOL-1-YL)-2-PROPANOL DERIVATIVES SUBSTITUTED WITH A STYRYL GROUP | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-05-15 | — | — | US | disclosed |
| EP-0174769-A1 | Antifungal azole compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-03-19 | — | — | EP | disclosed |
| EP-0165775-A1 | Antifungal azole compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288315-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUND | CYP51A1, KMO, TALDO1 | CES2 663/4885CES1 106/4885PTPN1 4327/4885 |
| US-20250170117-A1 | MODULATORS OF ACKR3 AND USES THEREOF | ACKR3, PROKR2, PROKR1 | CES2 3096/4885CES1 2441/4885PTPN1 3832/4885 |
| US-20250257058-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMO | PELI1, MALT1, MCTS1 | CES2 2194/4885CES1 233/4885PTPN1 80/4885 |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | GBA1, PIKFYVE, MAN2B1 | CES2 1314/4885CES1 108/4885PTPN1 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.